Literature DB >> 34104323

Loperamide Toxicity Revealing Apical Hypertrophic Cardiomyopathy.

Najah Khan1, Kalyan R Chitturi1, Courtney Hatcher1, Marietta Clewing1, Sherif F Nagueh2.   

Abstract

Loperamide, a μ-opioid receptor agonist, can cause cardiotoxicity by inhibiting the potassium ion channel and slowing cardiomyocyte repolarization. This, in turn, can lead to frequent early afterdepolarizations, the most common mechanism of drug-induced long QT syndrome and torsades de pointes. Apical hypertrophic cardiomyopathy (AHCM) is a nonobstructive hypertrophic cardiomyopathy rarely associated with malignant arrhythmias. We present a case of loperamide-induced malignant ventricular arrhythmia revealing underlying AHCM in a 25-year-old woman with a history of sudden cardiac arrest (SCA) and opioid use. It is important to evaluate for structural heart disease in all patients presenting with SCA, regardless of presumed etiology such as drug-induced cardiotoxicity, to prevent missed opportunities for adequate treatment. Furthermore, the diagnosis of AHCM in SCA warrants further genetic evaluation for variances with a predilection for malignant arrhythmias.

Entities:  

Keywords:  apical hypertrophic cardiomyopathy; loperamide; structural heart disease; sudden cardiac arrest; ventricular tachycardia

Mesh:

Substances:

Year:  2021        PMID: 34104323      PMCID: PMC8158447          DOI: 10.14797/VRZW9460

Source DB:  PubMed          Journal:  Methodist Debakey Cardiovasc J        ISSN: 1947-6108


  7 in total

1.  Cardiac conduction disturbance after loperamide abuse.

Authors:  J M Marraffa; M G Holland; R W Sullivan; B W Morgan; J A Oakes; T J Wiegand; M J Hodgman
Journal:  Clin Toxicol (Phila)       Date:  2014-11       Impact factor: 4.467

2.  An Emerging Malignant Arrhythmia Epidemic Due to Loperamide Abuse: Underlying Mechanisms and Clinical Relevance.

Authors:  Stanley Nattel
Journal:  JACC Clin Electrophysiol       Date:  2016-12-19

3.  Risk of death in long-term follow-up of patients with apical hypertrophic cardiomyopathy.

Authors:  Kyle W Klarich; Christine H Attenhofer Jost; Josepha Binder; Heidi M Connolly; Christopher G Scott; William K Freeman; Michael J Ackerman; Rick A Nishimura; A Jamil Tajik; Steve R Ommen
Journal:  Am J Cardiol       Date:  2013-03-27       Impact factor: 2.778

4.  Mutations in the Kv1.5 channel gene KCNA5 in cardiac arrest patients.

Authors:  Nathalie H Nielsen; Bo G Winkel; Jørgen K Kanters; Nicole Schmitt; Jacob Hofman-Bang; Henrik S Jensen; Bo H Bentzen; Bjarne Sigurd; Lars A Larsen; Paal S Andersen; Stig Haunsø; Keld Kjeldsen; Morten Grunnet; Michael Christiansen; Søren-Peter Olesen
Journal:  Biochem Biophys Res Commun       Date:  2007-01-18       Impact factor: 3.575

Review 5.  A clinical approach to inherited hypertrophy: the use of family history in diagnosis, risk assessment, and management.

Authors:  Kyla E Dunn; Colleen Caleshu; Allison L Cirino; Carolyn Y Ho; Euan A Ashley
Journal:  Circ Cardiovasc Genet       Date:  2013-02

6.  Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography.

Authors:  J C C Moon; N G Fisher; W J McKenna; D J Pennell
Journal:  Heart       Date:  2004-06       Impact factor: 5.994

7.  The KCNE genes in hypertrophic cardiomyopathy: a candidate gene study.

Authors:  Paula L Hedley; Ole Haundrup; Paal S Andersen; Frederik H Aidt; Morten Jensen; Johanna C Moolman-Smook; Henning Bundgaard; Michael Christiansen
Journal:  J Negat Results Biomed       Date:  2011-10-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.